Regression of prostatic cancer metastasis by high doses of diethylstilbestrol diphosphate.
Diethylstilbestrol diphosphate (DES-P) has shown effective symptomatic relief in patients with metastatic carcinoma of the prostate. Although there is little known about its role in soft tissue metastasis, our experience in 3 patients with advanced carcinoma of the prostate infiltrating the trigone and ureterovesical junction revealed significant improvement of hydronephrosis. All patients failed to respond to conventional doses of stilbestrol. Diethylstilbestrol diphosphate is recommended in the treatment of advanced carcinoma of the prostate with soft tissue metastasis. It is safe and effective, and the tumor responses outweigh the side effects of the drug. The mechanism of action of this compound is discussed.
D000368:Aged; D001859:Bone Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000150:complications / Q000188:drug therapy*; D004054:Diethylstilbestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006869:Hydronephrosis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*
D004054:Diethylstilbestrol; C004955:fosfestrol